237 related articles for article (PubMed ID: 24743915)
21. Prognostic value of pretreatment 18F-FDG PET in patients with primary central nervous system lymphoma: SUV-based assessment.
Kawai N; Zhen HN; Miyake K; Yamamaoto Y; Nishiyama Y; Tamiya T
J Neurooncol; 2010 Nov; 100(2):225-32. PubMed ID: 20390437
[TBL] [Abstract][Full Text] [Related]
22. Hyperaccumulation of (18)F-FDG in order to differentiate solid pseudopapillary tumors from adenocarcinomas and from neuroendocrine pancreatic tumors and review of the literature.
Guan ZW; Xu BX; Wang RM; Sun L; Tian JH
Hell J Nucl Med; 2013; 16(2):97-102. PubMed ID: 23687644
[TBL] [Abstract][Full Text] [Related]
23. Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions.
Okada M; Shimono T; Komeya Y; Ando R; Kagawa Y; Katsube T; Kuwabara M; Yagyu Y; Kumano S; Imaoka I; Tsuchiya N; Ashikaga R; Hosono M; Murakami T
Ann Nucl Med; 2009 Jun; 23(4):349-54. PubMed ID: 19340526
[TBL] [Abstract][Full Text] [Related]
24. Differential diagnosis between (18)F-FDG-avid metastatic lymph nodes in non-small cell lung cancer and benign nodes on dual-time point PET/CT scan.
Suga K; Kawakami Y; Hiyama A; Sugi K; Okabe K; Matsumoto T; Ueda K; Tanaka N; Matsunaga N
Ann Nucl Med; 2009 Aug; 23(6):523-31. PubMed ID: 19444550
[TBL] [Abstract][Full Text] [Related]
25. The Role of 18F-FDG PET/CT in the evaluation of Ascites of Undetermined Origin.
Zhang M; Jiang X; Zhang M; Xu H; Zhai G; Li B
J Nucl Med; 2009 Apr; 50(4):506-12. PubMed ID: 19289438
[TBL] [Abstract][Full Text] [Related]
26. Current generation time-of-flight (18)F-FDG PET/CT provides higher SUVs for normal adrenal glands, while maintaining an accurate characterization of benign and malignant glands.
Koopman D; van Dalen JA; Stigt JA; Slump CH; Knollema S; Jager PL
Ann Nucl Med; 2016 Feb; 30(2):145-52. PubMed ID: 26644009
[TBL] [Abstract][Full Text] [Related]
27. 18F-FDG PET of common enhancing malignant brain tumors.
Kosaka N; Tsuchida T; Uematsu H; Kimura H; Okazawa H; Itoh H
AJR Am J Roentgenol; 2008 Jun; 190(6):W365-9. PubMed ID: 18492879
[TBL] [Abstract][Full Text] [Related]
28. FDG-PET in immunocompetent patients with primary central nervous system lymphoma: correlation with MRI and clinical follow-up.
Palmedo H; Urbach H; Bender H; Schlegel U; Schmidt-Wolf IG; Matthies A; Linnebank M; Joe A; Bucerius J; Biersack HJ; Pels H
Eur J Nucl Med Mol Imaging; 2006 Feb; 33(2):164-8. PubMed ID: 16220304
[TBL] [Abstract][Full Text] [Related]
29. Variety in bone marrow 18F-FDG uptake in Hodgkin lymphoma patients without lymphomatous bone marrow involvement: does it have an explanation?
Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
Nucl Med Commun; 2016 Jan; 37(1):23-9. PubMed ID: 26440567
[TBL] [Abstract][Full Text] [Related]
30. [Value of dual-time-point (18)F-fluorodeoxyglucose integrated positron emission and computed tomography in differentiation of malignant from benign gastrointestinal diseases].
Xu XX; Cheng J; Xu WG; Dai D; Song XY; Ma WC; Zhu L; Zhu X
Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):364-8. PubMed ID: 22883458
[TBL] [Abstract][Full Text] [Related]
31. The Role of Dual-Phase FDG PET/CT in the Diagnosis and Follow-Up of Brain Tumors.
Özütemiz C; Neil EC; Tanwar M; Rubin NT; Ozturk K; Cayci Z
AJR Am J Roentgenol; 2020 Oct; 215(4):985-996. PubMed ID: 32841063
[No Abstract] [Full Text] [Related]
32. The value of dual time point (18)F-FDG PET imaging for the differentiation between malignant and benign lesions.
Lan XL; Zhang YX; Wu ZJ; Jia Q; Wei H; Gao ZR
Clin Radiol; 2008 Jul; 63(7):756-64. PubMed ID: 18555033
[TBL] [Abstract][Full Text] [Related]
33. Diagnostic value of using 18F-FDG PET and PET/CT in immunocompetent patients with primary central nervous system lymphoma: A systematic review and meta-analysis.
Zou Y; Tong J; Leng H; Jiang J; Pan M; Chen Z
Oncotarget; 2017 Jun; 8(25):41518-41528. PubMed ID: 28514747
[TBL] [Abstract][Full Text] [Related]
34. Utility of brain FDG-PET in primary CNS lymphoma.
Mohile NA; Deangelis LM; Abrey LE
Clin Adv Hematol Oncol; 2008 Nov; 6(11):818-20, 840. PubMed ID: 19194366
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of FDG uptake in pulmonary hila with FDG PET/CT and contrast-enhanced CT in patients with thoracic and non-thoracic tumors.
Gedik GK; Kara PO; Kara T; Sari O; Kara F
Ann Nucl Med; 2010 Oct; 24(8):593-9. PubMed ID: 20665251
[TBL] [Abstract][Full Text] [Related]
36. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
37. Dual-time-point F-18 FDG PET/CT imaging for differentiating the lymph nodes between malignant lymphoma and benign lesions.
Nakayama M; Okizaki A; Ishitoya S; Sakaguchi M; Sato J; Aburano T
Ann Nucl Med; 2013 Feb; 27(2):163-9. PubMed ID: 23188388
[TBL] [Abstract][Full Text] [Related]
38. 18F-2-fluoro-2-deoxyglucose uptake in white adipose tissue on pediatric oncologic positron emission tomography (PET)/computed tomography (CT).
Wong KK; Sedig LK; Bloom DA; Hutchinson RJ; Shulkin BL
Pediatr Radiol; 2020 Apr; 50(4):524-533. PubMed ID: 31776602
[TBL] [Abstract][Full Text] [Related]
39. Intratumoral heterogeneity of F-18 FDG uptake differentiates between gastrointestinal stromal tumors and abdominal malignant lymphomas on PET/CT.
Watabe T; Tatsumi M; Watabe H; Isohashi K; Kato H; Yanagawa M; Shimosegawa E; Hatazawa J
Ann Nucl Med; 2012 Apr; 26(3):222-7. PubMed ID: 22187313
[TBL] [Abstract][Full Text] [Related]
40. The maximum standardized uptake value of fluorodeoxyglucose positron emission tomography of the primary tumour is a good predictor of pathological nodal involvement in clinical N0 non-small-cell lung cancer.
Miyasaka Y; Suzuki K; Takamochi K; Matsunaga T; Oh S
Eur J Cardiothorac Surg; 2013 Jul; 44(1):83-7. PubMed ID: 23233074
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
